Drug Trial Radar · NCT05387707
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Feb 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
287
Actual
Start
Aug 16, 2022
Primary completion
Feb 2, 2024
Study completion Feb 2, 2024
Sponsor
- Lead sponsor
- Cara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS) for moderate-to-severe pruritus in adult subjects with atopic dermatitis (AD).
Conditions
- Pruritus
- Atopic Dermatitis
Interventions
difelikefalin 0.25 mgDrug
Oral difelikefalin 0.25 mg tablets administered twice daily
difelikefalin 0.5 mgDrug
Oral difelikefalin 0.5 mg tablets administered twice daily
TCS CreamDrug
TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
PlaceboDrug
Oral Placebo tablets administered twice daily
Vehicle CreamDrug
Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients achieving an improvement from baseline ≥4 points with respect to the weekly mean of the daily 24-hour I-NRS score at Week 12Time frame: Week 12
Locations
61 sites in 1 country. Site status is shown where the registry gives one.
Cara Therapeutics Study Site
Scottsdale, Arizona
Cara Therapeutics Study Site
Fort Smith, Arkansas
Cara Therapeutics Study Site
Rogers, Arkansas
Cara Therapeutics Study Site
Fountain Valley, California
Cara Therapeutics Study Site
Lomita, California
Cara Therapeutics Study Site
Los Angeles, California
Cara Therapeutics Study Site
Redwood City, California
Cara Therapeutics Study Site
Sacramento, California
Cara Therapeutics Study Site
San Diego, California
Cara Therapeutics Study Site 2
Santa Monica, California
Cara Therapeutics Study Site
Santa Monica, California
Cara Therapeutics Study Site
Valencia, California
Cara Therapeutics Study Site
Denver, Colorado
Cara Therapeutics Study Site
Brandon, Florida
Cara Therapeutics Study Site
Coral Gables, Florida
Cara Therapeutics Study Site
Delray Beach, Florida
Cara Therapeutics Study Site
Hollywood, Florida
Cara Therapeutics Study Site
North Miami Beach, Florida
Cara Therapeutics Study Site
Orlando, Florida
Cara Therapeutics Study Site
Saint Augustine, Florida
Cara Therapeutics Study Site
St. Petersburg, Florida
Cara Therapeutics Study Site
Sweetwater, Florida
Cara Therapeutics Study Site
Tampa, Florida
Cara Therapeutics Study Site
Marietta, Georgia
Cara Therapeutics Study Site
Indianapolis, Indiana
Cara Therapeutics Study Site
Plainfield, Indiana
Cara Therapeutics Study Site
South Bend, Indiana
Cara Therapeutics Study Site
Overland Park, Kansas
Cara Therapeutics Study Site
Louisville, Kentucky
Cara Therapeutics Study Site
Baton Rouge, Louisiana
Cara Therapeutics Study Site
Houma, Louisiana
Cara Therapeutics Study Site
Metairie, Louisiana
Cara Therapeutics Study Site
New Orleans, Louisiana
Cara Therapeutics Study Site
Rockville, Maryland
Cara Therapeutics Study Site
Brighton, Massachusetts
Cara Therapeutics Study Site
Auburn Hills, Michigan
Cara Therapeutics Study Site
Clinton Township, Michigan
Cara Therapeutics Study Site
Detroit, Michigan
Cara Therapeutics Study Site
Waterford, Michigan
Cara Therapeutics Study Site
Hackensack, New Jersey
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.